Cell Cycle

List of Papers (Total 5,062)

Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.

BRD4: a BET(ter) target for the treatment of AML?

CRH-R splicing in estrogen-sensitive breast cancer.

DrICE resurrects Grim to antagonize DIAP1.

CDK modulation coordinates G 1 events after S phase.

Keeping EGFR signaling in check: ubiquitin is the guardian.

Skp2: a dream target in the coming age of cancer therapy.

SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers.

Senescence-accelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease.

CYLD coordinates with EB1 to regulate microtubule dynamics and cell migration.

Wild-type p53-induced phosphatase 1 (Wip1) forestalls cellular premature senescence at physiological oxygen levels by regulating DNA damage response signaling during DNA replication.

Tuberin in renal cell hypertrophy.

Mitochondrial alteration in type 2 diabetes and obesity: an epigenetic link.

Remodelers move chromatin in response to DNA damage.

Listeria monocytogenes induces host DNA damage and delays the host cell cycle to promote infection.

ATM in prevention of genomic instability.

PTEN-mediated ERK1/2 inhibition and paradoxical cellular proliferation following Pnck overexpression.

Distinctive effects of the cellular inhibitor of apoptosis protein c-IAP2 through stabilization by XIAP in glioblastoma multiforme cells.

Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.

Integrin-linked kinase in ciliary Hedgehog signaling.

Revelations from a bicistronic calcium channel gene.

Novel mechanism links p63 and cisplatin resistance.

Invading cancer cells are predominantly in G0/G1 resulting in chemoresistance demonstrated by real-time FUCCI imaging.

Copper is a potent inhibitor of both the canonical and non-canonical NFκB pathways.

Functional genomics identify Birc5/survivin as a candidate gene involved in the chronotoxicity of cyclin-dependent kinase inhibitors.